Cellix expands European distribution network with Tebu-bio

Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.

Cellix's range of biochips and accessories are now available for purchase from tebu-bio for a wide range of applications including investigation of platelet biology, thrombi formation, the leukocyte adhesion cascade; biofilm formation and colonisation; and oncology studies. These biochips are compatible with standard syringe pumps from Harvard Apparatus, World Precision Instruments, KD Scientific and many more.

Vivienne Williams, CEO, Cellix commented on the deal: "We are delighted to be working with tebu-bio given their vast experience in the field of cell biology and we believe this will be hugely beneficial to our customer base across Europe."

Dr. Jean-François Têtu, Cells & Cell-Based Assay Manager at tebu-bio, Le Perray-en-Yvelines, France; says "We are very pleased to be able to offer our clients throughout Europe access to these very innovative products, which clearly show tebu-bio's dedication to continuously introduce new products and technologies. Scientists will be able to monitor cell phenomena dynamically rather than statically with Cellix's biochips."

Cellix is an Irish based company producing a range of precise microfluidic pumping solutions and disposable biochips for cell-based assays in applied biological research and drug screening. Cellix's VenaFlux Platform and customised platforms provide continuous blood flow (via Mirus Nanopump) and simulate blood vessels (via capillaries in our range of biochips) in a robust in vitro micro-environment. Investigation of platelet biology, thrombi formation, the leukocyte adhesion cascade; biofilm formation and colonisation; and evaluation of stents and stent materials are key applications of our technology where customers cite the "reduction in blood sample required; ease of use and physiological relevance" of the assays as being of key importance. Customers include academics, blood centers and pharmaceutical and biotechnology companies around the world. The Company is headquartered in Dublin, and maintains an office in New York city. For further information on Cellix's biochip range, click here.

 www.tebu-bio.com and www.cellixltd.com